(Q37098098)

18 August 2017

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib (English)

1 reference

18 August 2017

5

David Zurakowski

1 reference

18 August 2017

Tammy F Chu

1

1 reference

18 August 2017

Maria A Rupnick

2

1 reference

18 August 2017

Risto Kerkela

3

1 reference

18 August 2017

Susan M Dallabrida

4

1 reference

18 August 2017

Lisa Nguyen

6

1 reference

18 August 2017

Kathleen Woulfe

7

1 reference

18 August 2017

Elke Pravda

8

1 reference

18 August 2017

Flavia Cassiola

9

1 reference

18 August 2017

Jayesh Desai

10

1 reference

18 August 2017

Suzanne George

11

1 reference

18 August 2017

Jeffrey A Morgan

12

1 reference

18 August 2017

David M Harris

13

1 reference

18 August 2017

Nesreen S Ismail

14

1 reference

18 August 2017

Jey-Hsin Chen

15

1 reference

18 August 2017

Frederick J Schoen

16

1 reference

18 August 2017

Annick D Van den Abbeele

17

1 reference

18 August 2017

George D Demetri

18

1 reference

18 August 2017

Thomas Force

19

1 reference

18 August 2017

Ming Hui Chen

20

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

18 August 2017

1 reference

18 August 2017

370

1 reference

18 August 2017

9604

1 reference

18 August 2017

2011-2019

1 reference

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Sunitinib in patients with metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

A small molecule-kinase interaction map for clinical kinase inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

STRESS signaling pathways that modulate cardiac myocyte apoptosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Mechanisms of hypertension associated with BAY 43-9006.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643085

Tyrosine kinases as targets for cancer therapy

3 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Targeted cancer therapeutics: the heartbreak of success

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Angiogenesis inhibitors and hypertension: an emerging issue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961865-0

7 January 2021

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18083403

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/S0140-6736(07)61865-0

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

18083403

1 reference